dm+d
Unassigned
New Medicines
Vosevi Hepatitis C infection in children aged 12 years and older - plus new 200/50/50mg strength tablet
Information
Vosevi
Licence extension / variation and new formulation
Gilead Sciences
Gilead Sciences
Development and Regulatory status
None
Approved (Licensed)
None
Sep 21Approved in EU [3].
Jul 21EU CHMP issues a positive opinion recommending an extension to the indication for Vosevi to include use in children aged 12 and older. The proposed new indication is treatment of chronic hepatitis C virus (HCV) infection in patients aged 12 years and older and weighing at least 30kg. The CHMP also recommended the addition of a new 200/50/50 mg strength for the film-coated tablets [2].
Category
Fixed dose combination of a pan-genotypic inhibitor of the HCV NS5B RNA-dependent RNA polymerase (sofosbuvir), pan-genotypic HCV inhibitor (velpatasvir) and a pan-genotypic inhibitor of the HCV NS3/4A protease (voxilaprevir)
Prevalence of HCV infection in children and adolescents has been reported to vary from 0.05% to 0.36% in the US and Europe [1].
Hepatitis C infection in children aged 12 years and older - plus new 200/50/50mg strength tablet
Oral